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Abstract 
Objective: This study (MEasurement Reactions In Trials) aimed to produce recommendations on how best to minimize bias from 
measurement reactivity (MR) in randomized controlled trials of interventions to improve health. 
Study design and setting: The MERIT study consisted of: (1) an updated systematic review that examined whether measuring 
participants had effects on participants’ health-related behaviors, relative to no-measurement controls, and three rapid reviews to identify: 
(i) existing guidance on MR; (ii) existing systematic reviews of studies that have quantified the effects of measurement on behavioral or 
affective outcomes; and (iii) studies that have investigated the effects of objective measurements of behavior on health-related behavior; 
(2) a Delphi study to identify the scope of the recommendations; and (3) an expert workshop in October 2018 to discuss potential 
recommendations in groups. 
Results: Fourteen recommendations were produced by the expert group to: (1) identify whether bias is likely to be a problem for 
a trial; (2) decide whether to collect data about whether bias is likely to be a problem; (3) design trials to minimize the likelihood of 
this bias. 
Conclusion: These recommendations raise awareness of how and where taking measurements can produce bias in trials, and are 
thus helpful for trial design. © 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license 
( http:// creativecommons.org/ licenses/ by/ 4.0/ ) 
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What is New? 
• The MERIT study was funded by MRC-NIHR to 
produce recommendations about identifying, and 
ameliorating the effects of measurement on bias in 
trials of health-related outcomes. 
• This is the first set of recommendations on this 
source of bias. 
• Systematic reviews have established that measure- 
ment reactivity occurs, but it is not clear under what 
circumstances it is most likely and of largest effect. 
• Fourteen recommendations are presented here to 
support researchers handle the risk of bias result- 
ing from measurement reactivity by: 1) identifying 
whether such bias is likely to be a problem for any 
specific trial; 2) deciding whether to collect fur- 
ther data to inform decisions about whether bias is 
likely to be a problem for a particular study; and 3) 
designing trials to minimise the likelihood of bias 
from measurement reactivity. 
• Researchers are urged to use the recommendations 
presented here to improve their awareness of how 
and where taking measurements can lead to bias in 
trials, and to support the design of future trials that 
will have less risk of bias. 











































known as measurement reactivity (MR) [1] . Randomized
controlled trials (RCTs) always include measurements of
trial outcomes such as self-reports, objective measure-
ments of behavior and/or clinical markers, and possibly
further measurements as part of process evaluations. The
usual methods of conduct and analysis of trials implicitly
assume that measurements do not affect subsequent out-
come measurements or interact with the trial intervention,
and that any effects will be the same in each experimen-
tal group, and are therefore unlikely to bias treatment
comparisons [ 1 , 2 , 4 ]. Possible effects on participants are
ignored, and not considered as a potential source of bias. 
The most compelling evidence of MR is found in two
areas: (1) the question-behavior effect, where measurement
in the form of asking questions about behavior, produces
small changes in the behavior being asked about [ 3 , 5 , 6 ],
and (2) the effects of measuring physical activity using
pedometers (particularly where step counts can be read
by participants) producing increases in physical activity
[ 7 , 8 ]. In addition, there is also evidence from randomized
studies showing that completing questionnaires about the
consequences of illness results in people reporting higher
anxiety levels than people who have not completed them
[9] . Other measurement procedures widely employed in
RCTs, such as assessing bodyweight, are also used as in-
tervention techniques in their own right, as they are seen
to be effective at producing behavior change [10] . In manyareas of research the possibility of MR has been insuffi-
ciently considered or investigated [11] . As a consequence,
MR is not adequately addressed within existing guidelines
for designing, reporting and appraising trials. 
The MERIT (MEasurement Reactions In Trials) study
was funded by the MRC and NIHR [12] to produce rec-
ommendations on how and where taking measurements can
lead to bias and to provide recommendations to minimize
such bias. It involved updating a systematic review, con-
ducting three rapid systematic reviews and a Delphi study,
to generate an evidence base, which an expert workshop
used to produce recommendations. The full methods for
the MERIT study and the findings from the evidence re-
views are published separately [ 6 , 12 ], a brief summary of
which is presented in Box 1. The present report provides
contextual background on how MR can lead to bias and
a summary of the recommendations generated from the
MERIT study. 
Box 1 Evidence generated by MERIT 
study to inform production of current recom- 
mendations 
We updated an existing systematic review on the 
question-behavior effect to examine whether asking 
participants questions had effects on participants’ 
health-related behaviors. This updated review [6] con- 
cluded that these effects were statistically robust 
across 43 studies, , albeit small in size (standardized 
mean difference = 0.06, 95% CI 0.02–0.09) and het- 
erogeneous (I 2 = 54%). 
Three rapid systematic reviews were conducted. 
The first review established that there was no exist- 
ing guidance on MR. The second review identified 
existing systematic reviews that quantified the effects 
of measurement on outcomes, and found five such 
reviews that have examined the question-behavior ef- 
fect, with no review of the effects of measurement on 
affective outcomes (such as feelings and emotions) in 
health and non-health contexts. The third review iden- 
tified 16 studies that had examined reactive effects of 
objective measurements of behavior on health-related 
behavior, with most evidence of reactivity focused on 
physical activity and showing small effects and short 
duration. 
A Delphi procedure sought the views of 40 ex- 
perts to define the scope of the recommendations, in 
two waves of data collection, and substantial agree- 
ment was reached. Finally, a workshop involved dis- 
cussion of potential recommendations by 23 experts. 
Recommendations were formed through discussion in 
groups, with no formal voting procedure to indicate 
consensus being required. 




















































































2. Measurement reactivity and risk of bias 
To inform recommendations about how to limit bias due
to MR, we identified six plausible scenarios in which MR
may produce bias. It is important to note that the existence
of MR is not sufficient by itself to produce bias in a trial’s
intervention effect estimate. 
2.1. Different measurement protocols across trial arms 
Bias may arise when different measurement protocols
are used across randomized trial arms, with one trial arm
being measured differently from another. If measurement
impacts on trial outcomes, greater disparities in measure-
ment protocols will produce greater bias. For example, par-
ticipants in the experimental condition may complete the
following measurements, whilst participants in the con-
trol condition are not asked to complete such measures:
(1) process measures to assess intervention mechanisms
of effect, (2) momentary assessments of behavior or treat-
ment response (ie, repeated data collection in an individ-
ual’s usual environment, at or close to the time they carry
out that behavior) using technology such as a digital ap-
plication, or (3) intervention feedback or fidelity assess-
ment (to determine whether the intervention is delivered
as intended). These measures carry the potential to im-
pact upon a participant’s experience of the intervention,
negatively or positively. For example, the measures could
serve as reinforcers, reminders or boosters of intervention
effects, and thus can exaggerate the apparent effects of
interventions. 
2.2. Contamination 
Contamination refers to the inadvertent exposure of a
non-experimental control group to intervention content that
is an integral part of an effective experimental group treat-
ment. For instance, if a pedometer were one interven-
tion component in a multi-component intervention to in-
crease physical activity, then its use as a measure to eval-
uate change in physical activity in both arms is intrinsi-
cally problematic, as the non-intervention control group
are gaining access to part of the intervention. Similarities
between the contents of research measurements and in-
terventions provide grounds for concern about bias being
induced by contamination. In this situation, estimates of
effectiveness are likely to be biased towards the null, as
both intervention and control groups are exposed to similar
content. 
2.3. Interactions between measurement and intervention 
Where research procedures mimic the effect of the in-
tervention via similar mechanisms, this may produce bias,
even when the research procedure is not part of the in-
tervention. For example, self-monitoring may be promotedin a study by both a measurement procedure such as self-
weighing and an intervention procedure such as regular
use of a bodyweight diary. Thus, the use of self-weighing
as a measurement procedure may interfere with compar-
isons between randomized groups, as both may be ex-
posed to content that underpins the anticipated effect of
the intervention. In this example, the biasing effect will
be similar to that of contamination, that is, towards the
null. In principle, bias could go in either direction: for ex-
ample, research measurement could prepare experimental
group participants to be more receptive to an intervention
by prompting contemplation of the reasons for behavior
change [4] . 
2.4. Ceiling effects 
Restrictions on the possible range of measured out-
comes can interact with MR where measurement impacts
on both arms in a two-arm trial [4] . For example, there
may be a finite limit to the amount of fruit and vegetables
that a dietary intervention can reasonably stimulate. The
more that measurement procedures unintentionally stimu-
late the behavior that is the target of the intervention, the
less scope there is for the intervention to stimulate changes
in diet further and hence be more effective than the control.
2.5. Measurement reactivity as a component of 
performance bias 
Where MR is present, there are both clinical and re-
search practices associated with measurement that can lead
to bias, rather than the measurement per se . For exam-
ple, the process of collecting measurement data during the
course of a trial may alter the care provided by healthcare
professionals (eg, more or less attention, ancillary treat-
ment and diagnostic investigations), which may lead to bias
if such alterations are implemented differently for random-
ized groups. For example, one group of patients may have
more frequent contact with healthcare professionals as a re-
sult of regular assessment of bodyweight, blood pressure,
or blood tests to assess liver function. This is a specific
case of the wider class of performance bias. 
2.6. Effects on attrition bias 
Reactions to measurement can also be implicated in
other forms of bias. For example, from the participant’s
perspective, too much measurement can increase the bur-
den of trial participation so that they decide to drop out.
Where the burden differs between intervention and control
group participants, MR may be more likely to produce dif-
ferential attrition. 
3. Recommendations 
Recommendations produced by the expert workshop
were grouped into three broad types: first, identifying



























































































whether bias is likely to be a problem for any specific trial;
second, deciding whether to collect further data to inform
decisions about whether bias is likely to be a problem;
and third, how to design trials to minimize the likelihood
of this form of bias. 
3.1. Identify whether measurement reactivity is likely to 
be a major source of bias for a trial 
In many circumstances, whilst bias from MR may be
present, it is often likely to be of small magnitude [6] com-
pared to other potential sources of bias, such as failure of
randomization [13] , and so can safely be ignored. How-
ever, it is worth considering that reactions to assessment
can exacerbate or contribute to other sources of bias that
are already well-recognized [2] . 
Recommendation 1. Consider potential for measurement
reactivity causing bias at the outset of designing a trial. 
It will be easier to prevent MR causing bias than to deal
with the consequences of bias through analysis after the
event. Given this, researchers should consider at the out-
set whether the trial they are planning is likely to produce
bias. It is important to consider the many measurement
and assessment processes involved in a trial, including as-
sessment of eligibility, baseline assessments, assessments
of adherence, assessments of fidelity, process evaluations
(quantitative and qualitative), and interim and final out-
come assessments. It is necessary to be clear where mea-
surements are integral to an intervention (ie, as would be
rolled out in practice), and to make decisions about re-
search measurements in light of this knowledge. 
Recommendation 2. Consider potential for measurement
reactivity as a source of bias at all stages of the research
process. 
It is important to consider all instances of measurement
throughout the research process and how participants may
react. For instance, when assessing eligibility of a poten-
tial trial participant, disclosure of health status (eg, blood
pressure or cholesterol level) could make participants more
or less receptive to an intervention [14] . Baseline mea-
surements in a trial typically contribute to efficient design
by enabling more precise estimation of the intervention
effect. However, experiences of earlier measurement may
influence responses at later measurement occasions and/or
interact with the study intervention [11] . The prospect of
future measurement may also produce changes in research
participants. Further, electronic monitoring of medication
adherence can lead to changes in adherence [15] . That is,
knowledge or anticipation of measurement or disclosure
of outcomes should be considered as potential sources of
reactivity, as well as actual measurements conducted. Con-
sider also people delivering interventions, who may exhibit
greater adherence to intervention protocols when their de-
livery is recorded in a trial than would otherwise be thecase. Standard Operating Procedures for measurement pro-
cedures should be consistent across trial arms, reduce un-
necessary measurement occasions etc., and also address in-
formal contacts/communications regarding assessment be-
tween trial participants and health care providers or trial
personnel. 
Recommendation 3. Consider specific trial features that
may indicate heightened risk of bias due to measurement
reactivity ( Table 1 ) . 
Table 1 provides a series of trial features that might
indicate where MR is a possible risk of bias in a study,
based on the views of experts informed by evidence re-
views [12] . The entries in Table 1 , or “red flags” features
of study design, indicate potential for bias from MR. This
may prove absent on closer examination, or identified but
mitigated through careful study design. The potential for
measurement as a co-intervention leading to bias is not
widely articulated in existing tools intended to assist study
design. 
Recommendation 4. Theorize potential measurement re-
actions as part of a logic model of how an intervention is
intended to work. 
It is good practice to construct a logic model that spec-
ifies how an intervention results in the intended outcomes
and helps in selecting appropriate measures and makes
theory explicit in a trial [16] . It has also been proposed
to develop models of “dark logic” by which interven-
tions may produce unintended harmful effects, to better
understand such phenomena [17] . In line with this pro-
posal, researchers may explicitly theorize to what extent
the risk of bias scenarios above may be applicable to
their trial. This could involve potential research partici-
pants, as well as drawing on the knowledge of the research
team. 
Recommendation 5. Consider the potential impact of
measurement procedures on participants in comparison
with the intensity and duration of the studied intervention.
While regular contact with research personnel may help
sustain participants’ engagement and thereby continuation
in a trial, it may be preferable to use non-measurement
related activities (such as newsletters etc.) to support par-
ticipants’ engagement. Circumstances in which the amount
of contact or interaction with researchers or clinicians for
baseline and follow-up measures are greater than interven-
tion exposure are of particular concern, for example, in
evaluations of brief interventions. 
Recommendation 6. Consider how participants may use
measurement to meet their own aims 
It may be helpful to consider participants as motivated
or rationally pursuing personal goals when considering the
possible effects of MR in producing bias. This means pay-
ing careful attention to how participants engage with the
134 D.P. French et al. / Journal of Clinical Epidemiology 139 (2021) 130–139 
Table 1. Trial features that may indicate risk of bias due to measurement reactivity 
Criterion indicating risk of bias Circumstances under which risk of bias is likely to be higher 
Participant selection 
Recruitment Selection on personal motivation for participation in the 
trial 
Eligibility criteria Restrictive eligibility criteria 
Education More educated e.g. university students 
Measurements 
Features of health outcome of interest 
Participant awareness of health-related 
outcome of interest 
Participants aware of outcome of interest (open) 
Nature of health-related outcomes Outcomes focussed on behaviour or anxiety; 
health-promoting behaviours such as physical activity 
Social desirability of health outcome Outcomes with well recognised social norms (e.g. 
bodyweight) 
Follow-up 
Number of measurement occasions Measurements repeated on several occasions 
Length of time to follow-up Short duration likely to be more affected by possible 
measurement effects 
Features of measurement procedures/tools 
Equivalence of measurement procedures 
across trial arms 
Differential across trial arms 
Similarity between measurement and 
behaviour change techniques 
Measurement directly mimics behaviour change 
techniques 
Source of data New data collected specifically for this study 
Measurements open to subjectivity Self-report measures 
Disclosure of measured values to 
participants 
Values disclosed to participants (immediately) 
Burden of measurement task Onerous for participant 
Complexity of measurement task Complex for participant 
Measurement framed in terms of 
goals/targets 
Participants measured against specific goals/targets 
Context Laboratory setting (as opposed to field or community 
settings) 
Interventions and comparators 
Nature of the intervention Behavioural and/or self-monitoring components included. 
Blinding to arm allocation Lack of blinding to arm allocation 
Process evaluation 
Process measures Measures included are assessing mechanisms of action on 
the primary outcome 
Timing Conducted before/during trial outcome assessments 
Trial arms included Conducted only in one trial arm 



















features of trial design. For instance, people may wish to
take part in a trial to gain access to outcome measurements
such as blood pressure or to receive regular feedback on
their activity levels from an accelerometer. 
Where participants are being assessed by healthcare
professionals with whom they have regular contact, they
may wish to respond in such a way as to create a par-
ticular impression of need (to elicit services), or compe-
tence (if they wish to create a productive relationship).
Thus, regular measurement may produce changes in self-reported outcomes. In the absence of blinding, partici-
pants in trials may exaggerate the personal benefits of
a treatment, if they believe that the treatment should be
more widely available. Arguably, the more extensive or
meaningful the measurement is to the participant within
a trial, for example, when involving additional checks
for people with diabetes, or regular monitoring for re-
lapse in people who have had cancer, the more likely
that participants may use measurements to meet their own
aims. 
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What is the expected effect size of the intervenon?
Weigh up concerns regarding MR against trial design features that are crical to address the 
research queson(s), recruitment and retenon of parcipants, other potenal sources of bias, 
resources available and ethical concerns





Does the trial have red flag features (see table 1)?Many red flag 
features 
present
If the size of 
ancipated 














Several red flag features present
Consider SWATs and/or pilot work to test whether red flag features lead to MR in your specific trial context
Follow recommendaons to minimise risk of MR bias
Example: invesgate 
potenal reacons 
to measurement in 
target parcipants
Example: invesgate 
duraon of potenal 
measurement 
reacons to inform 
trial design
Example: invesgate 








Fig. 1. Flowchart to support decision making for recommendation 7. 
∗Solomon 4 group design: a factorial design trial in which participants are randomized to intervention and control trial arms, as well as to baseline 











































3.2. Collect further data to inform decisions about risk of
bias resulting from measurement reactivity 
Given the limitations of existing knowledge, researchers
will sometimes have reason to be concerned that MR may
be a problem for their trial, but find it challenging to as-
sess risk of bias. In such circumstances, it may be sensible
to collect further quantitative or qualitative information to
inform decisions about potential modifications to trial de-
sign. 
Recommendation 7. Consider whether MR concerns for
your trial warrant further empirical examination. 
Having gone through processes indicated above, a
judgement is required about the likelihood of risk of bias
resulting from MR for a particular trial, and whether any
further action is needed. Fig. 1 shows a flowchart to sup-
port decision making with options ranging from taking no
further action and proceeding with the trial as planned, to
further investigation. 
Action taken needs to be proportionate and weighed
against other priorities and concerns. In some situations, it
may be appropriate to investigate likelihood of MR in fea-
sibility studies. Qualitative studies could be informative in
terms of understanding how people could potentially react
to measurements. A further possibility is the incorporationof nested methodological studies (studies within a trial,
SWATs) to estimate the magnitude of bias from MR in a
subset of participants. The size of a SWAT is necessar-
ily constrained by the size of the host trial and so results
may be imprecise. A SWAT can nevertheless contribute
to the overall body of evidence if results are combined
in meta-analyses. Intensive approaches such as a Solomon
four-group design are warranted only in trials where sev-
eral indicators suggest that MR is a major concern and
likely to bias effect estimation. Solomon designs involve
a factorial design in which participants are randomized to
intervention and control trial arms, as well as to baseline
assessment or no baseline assessment [11] . An alternative
approach is to consider a large simple trial that eschews
baseline measurement altogether, thus relying on random-
ization of large numbers to generate equivalence between
arms to safeguard the experimental design. 
Recommendation 8. Examine feedback from research per-
sonnel regarding research participants’ reports of changes
in their behavior/thoughts/emotions as a result of measure-
ment. 
During the course of a trial, research personnel may of-
ten have several informal conversations with participants.
It is possible that research participants might volunteer in-


























































































formation about changes in behavior, thoughts or attitudes
that have arisen from their participation in the trial, or
specifically from measurement procedures. Including pro-
vision for the gathering of such material may be worth
considering prior to seeking ethical approval. Where re-
search personnel consistently provide feedback regarding
the presence of MR, this could inform further process eval-
uations, statistical analysis strategies and/or interpretation
of study findings. 
3.3. Potential actions to minimize risk of bias from 
measurement reactivity within a trial 
Where consideration of the issues suggests that MR is
likely to cause bias within a trial, a number of options are
available. 
Recommendation 9. Consider possible measurement re-
activity when determining the overall burden of measure-
ment in a trial. 
Many patient-reported outcomes are collected during re-
search, but often not analyzed or reported [18] . This has
many downsides, including being an unethical use of par-
ticipant time (especially when they are in poor health),
respondent fatigue and lower response rates leading to
poorer quality data. These are arguments for reducing mea-
surement in trials. In addition, where measurements may
induce reactivity, having less measurement may limit the
scope for bias. 
Measures of intervention process help researchers un-
derstand how and when effects are produced [16] . How-
ever, researchers may wish to consider when it is appro-
priate for all participants to complete all measures. Process
measures typically assess hypothesized determinants of be-
haviors, such as attitudes or intentions. There is good evi-
dence that asking people to complete these kinds of mea-
sures can affect behavior [3] . Asking all research partici-
pants to complete process measures will almost certainly
be unnecessary as, if the hypothesized mechanism of ac-
tion is correct, the effect size will be considerably larger
than will be the case for the main outcome measure. It is
reasonable therefore to ask only a subset of participants
to complete process measures. Similarly, it may also be
efficient to investigate two or more hypothesized causal
pathways with randomly drawn, or targeted, sub-samples
of participants in a single trial, with the same primary out-
come measure. 
Recommendation 10. Embed measurement procedures
into routine clinical practice where possible. 
The use of unobtrusive measures has long been recom-
mended to avoid problems of measurement affecting par-
ticipants in research [19] . It will often be desirable to use
measurements that are not collected primarily for research
purposes, for example data in routine health records or ex-isting data collected for other purposes to minimize the
threat of bias from MR. 
Recommendation 11. Use identical measurement proto-
cols in all arms of a trial. 
In line with established good practice for trial design,
it is desirable to ensure that measurement procedures are
identical across all arms of a trial. This involves ensuring
that all measurements are completed in the same setting at
the same frequency and time-points, and where relevant,
by the same types of people (eg, research nurses, GPs).
Format and methods should also be identical; for exam-
ple, online/pencil and paper questionnaire, semi-structured
interviews. 
Sometimes differential measurement procedures across
arms of a trial are employed to help address the research
question, for example, to monitor physiological effects in
the intervention group only. Researchers in these types of
studies should consider the implications carefully. In gen-
eral, having balanced measurement across conditions in-
troduces fewer problems than having unbalanced measure-
ment, although having as little measurement as possible is
usually the least problematic. 
Recommendation 12. Avoid overlap between measure-
ment and intervention. 
Some measurement techniques are similar, if not iden-
tical, to intervention techniques designed to change health-
related behavior. For example, as noted earlier, pedometers
are an efficient method of allowing people to self-monitor
their behavior, when the users are not blinded to outcome.
Use of pedometers leading to self-monitoring is a spe-
cific case of a general issue: it is a clear threat to the
validity of a trial if measurement techniques are used that
closely resemble one or more behavior change techniques
that the trial is designed to evaluate. To inform theoriz-
ing about how the measurements may constitute active in-
terventions, a standardized taxonomy has distinguished 93
techniques for changing behavior [20] . Measurement can
mimic several of these techniques, by for example, serv-
ing as a prompt, promoting monitoring behavior, outcomes
or emotional reactions, providing feedback on behavior or
physiological indices, altering attention to previous suc-
cesses or failures, and providing information about health
threats. 
Recommendation 13. Consider the potential benefits of
masking measures and/or withholding feedback of mea-
sured values. 
Withholding information about which health-related
measures are being collected, or the purposes or values
of such measurements, could sometimes help reduce the
risk of MR producing bias. In certain circumstances the
aims of the research may be compromised by giving full
information prior to data collection; this is particularly per-
tinent when there is potential for MR. For example, there
























































































is evidence that covert sealed pedometers (described as
“posture monitors” to participants) do not lead to MR (in-
creased physical activity) compared to use of an unsealed
pedometer [8] . 
Information given to potential research participants,
however, needs to be comprehensive to facilitate fully in-
formed consent. It is therefore imperative that ethical con-
siderations are taken into account before making deci-
sions on masking of measurements are made. Where an
essential element of the research design would be com-
promised by full disclosure to participants, the withhold-
ing of information should be specified and appropriately
justified in the trial protocol and ethical approval submis-
sion. It is crucial that the research objective has strong
scientific merit and that an appropriate risk management
and harm alleviation strategy is in place. Further, the
amount of information withheld and the delay in disclos-
ing the withheld information should be kept to the absolute
minimum. 
Recommendation 14. If measurement reactivity is likely
to be present, investigations for measurement reactivity
should be included a priori in the statistical analysis plan.
If there is some reasonable likelihood of MR being
present, quantitative investigations of MR should be in-
cluded a priori in the trial protocol and statistical analysis
plan. These investigations could include sensitivity anal-
yses based on, for example, a subgroup of trial partici-
pants measured more intensively in a sub-study in both
trial arms. 
Statistical analyses should also be informed by feasi-
bility and pilot work (see recommendation 7). For exam-
ple, for some measurement procedures such as blood pres-
sure, self-reported anxiety or step count using pedometers,
the first one or two measurements are particularly reactive.
For this reason, some researchers collect multiple baseline
measurements, but do not use all of them. Data from a
feasibility trial could be explored to investigate MR in, for
example, the first 1–2 days of measurement. When com-
paring multiple trials in a systematic review, the reviewers
could consider MR as a source of heterogeneity; for ex-
ample, investigating trials based on measurement charac-
teristics. 
4. Conclusions 
The present recommendations are designed to raise
awareness of how and where taking measurements can lead
to bias in trials, so that future studies will have less risk
of bias. 
We acknowledge that trialists already have a wide range
of factors to consider in trial design, and that action taken
to address the risk of bias from MR needs to be propor-
tionate and weighed against other priorities and concerns.
We hope the practical tools ( Table 1 and Fig. 1 ) providedalongside these recommendations support researchers in
making these decisions. 
A key finding of the present work is that MR has not
been adequately addressed within existing guidelines for
designing, reporting (eg, CONSORT) [21] and appraising
trials (eg, risk of bias frameworks) [13] . We recommend
future iterations of these guidelines refer to our recommen-
dations as a basis to consider where measurement can lead
to bias in trials and make revisions where appropriate. For
example, it may be useful to consider to what extent the
six proposed mechanisms of MR are covered by existing
risk of bias frameworks. 
Finally, we hope that the many uncertainties identified
here act as a stimulus to improved research of this ne-
glected source of bias in trials. 
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